IGTP in 2025: 12 selected news stories
We look back at the year's most significant news stories, showcasing the dedication and collaboration that define IGTP.
At the IGTP TODAY
News
DM1-Hub launches as a national multi-centre study to transform research and care for Myotonic Dystrophy type 1
On 2 June, IGTP hosted the kick-off event for the DM1-Hub, a multicentre project driven by the the group GRENBA, which aims to create a comprehensive national registry of patients with Myotonic Dystrophy type 1 (DM1). The event brought together researchers, clinical professionals, institutional representatives and patient associations from across Spain.
- Research
HDAC11 deficiency improves muscle function and regeneration during ageing
Researchers from GRENBA-IGTP have identified the HDAC11 protein, an enzyme involved in cellular regulation, as a new therapeutic target to combat sarcopenia, the loss of muscle mass associated with ageing. The study shows that HDAC11 deficiency reduces muscle atrophy, preserves the muscle stem cell reservoir, promotes regeneration after injury and improves muscle function, opening the door to new strategies to support healthy ageing.
Can Ruti reaffirms its commitment to rare diseases in an interdisciplinary event
On Friday 28 February, HUGTiP and IGTP held a new edition of their event to mark Rare Disease Day. The event brought together healthcare professionals and researchers to share knowledge and experiences in the field. The program also included the patient perspective in the final part of the event.
Researchers from IGTP bring science to schools and inspire future generations
In this year’s edition of #científiques, fourteen researchers from IGTP have shared their expertise in various schools and secondary schools across Catalonia, offering students a first-hand and inspiring insight into their work in biomedical research.
IIS IGTP secures over €6.5 million through the Acción Estratégica en Salud 2024
The Instituto de Investigación Sanitaria IGTP has secured a total of €6,518,867 for various research projects and researcher contracts within the Acción Estratégica en Salud 2024 calls.
IGTP secures over €3.5 million to establish a national network addressing challenges of myotonic dystrophy type 1
IGTP has been awarded €3,547,417 in funding to conduct the "DM1-Hub" project, coordinated by Dr Gisela Nogales Gadea, leader of GRENBA, with Dr. Arturo López Castel of INCLIVA serving as co-principal investigator.
- Research
A new study reveals a promising therapy using a molecule that blocks microRNAs to treat myotonic dystrophy type 1
A team of researchers including the GRENBA group at IGTP has identified a promising therapy based on antimiRs to treat myotonic dystrophy type 1 (DM1). The results of their research have just been published in Science Advances.
- Research
New cellular models of myotonic dystrophy type 1 reflect the clinical diversity of the disease
Cellular models used to search for new therapies for myotonic dystrophy type 1 do not usually take into account the diversity of subtypes presented by patients. A study led by researchers from IGTP has taken a step forward by developing three new models that represent this heterogeneity. The results have been published in the journal iScience.
Can Ruti celebrates a Rare Disease Day symposium highlighting the importance of research to help patients
On Thursday 29 February, the Germans Trias Hospital hosted the 'International Rare Disease Day Symposium'. Health professionals and researchers from the Hospital and IGTP discussed their work in advancing the field of rare diseases. Representatives from patient associations of these diseases also participated.
